Ro 24-5913, (E)-4-[3-[2-(4-cyclobutyl-2- thiazolyl)ethenyl]phenylamino]-2,2-diethyl-4-oxobutanoic
acid, has been identified as a chemically unique, potent and selective
LTD4 antagonist. In vitro,
Ro 24-5913 competes with [3H]
LTD4 for its binding site on guinea pig lung membranes with an IC50 of 6.4 +/- 2.2 nM. In isolated guinea pig tracheal smooth muscle,
Ro 24-5913 produces concentration-dependent rightward shifts of LTD4-induced contraction curves (pA2 value of 9.6 +/- 0.2). The slope of the Schild plot is not significantly different from 1, indicating that the antagonism is of a competitive nature. In the human bronchus,
Ro 24-5913 is an effective antagonist of LTD4-induced contractions (pKB of 9.3 +/- 0.1). In vivo,
Ro 24-5913 dose-dependently inhibits LTD4-induced bronchoconstriction in guinea pigs by the i.v. (ID50 0.13 mg/kg), oral (ID50 0.12 mg/kg) and
aerosol (IC50 0.008%) routes of administration. This in vivo activity is specific as evidenced by the inability of
Ro 24-5913 to inhibit bronchoconstriction induced by
LTB4, PAF or
histamine. In comparison with other
LTD4 antagonists evaluated in this guinea pig model,
Ro 24-5913 is markedly superior in terms of oral potency, bioavailability and oral duration of action.
Ro 24-5913 also blocks allergic
bronchospasm mediated by endogenously generated
leukotrienes in guinea pigs; the potency and duration of action is nearly equivalent to that seen as an antagonist of bronchoconstrictions produced by exogenous
LTD4. In summary,
Ro 24-5913 is representative of a novel chemical class of
LTD4 receptor antagonists.(ABSTRACT TRUNCATED AT 250 WORDS)